A 52-year-old man with chronic kidney disease (eGFR 28 mL/min/1.73m²) presents with fatigue and dyspnea. His hemoglobin is 7.8 g/dL, MCV 82 fL, reticulocyte count 1.2% (normal 0.5–2.5%). Iron studies are normal. What is the most appropriate next step in management?

Question

Accepted Answer

B. Initiate erythropoiesis-stimulating agent (ESA) therapy. ## Clinical Diagnosis The patient has normocytic anemia (MCV 82 fL) with low reticulocyte count (1.2%) in the setting of chronic kidney disease (CKD). Normal iron studies exclude iron deficiency. This is anemia of chronic kidney disease (CKD-related anemia), primarily due to EPO deficiency. ## Pathophysiology of CKD-Related Anemia **Key Point:** In CKD, the kidneys produce <10% of normal EPO, leading to inadequate RBC production despite intact bone marrow function. The reticulocyte count is inappropriately low for the degree of anemia, confirming hypoproliferative anemia. ## Management Algorithm for CKD Anemia ```mermaid flowchart TD A[CKD patient with anemia]:::outcome --> B[Check iron studies]:::action B --> C{Iron replete?}:::decision C -->|No| D[Correct iron deficiency first]:::action C -->|Yes| E[Check reticulocyte count]:::decision E -->|Low| F[Hypoproliferative anemia]:::outcome F --> G{Hb target achieved?}:::decision G -->|No| H[Start ESA therapy]:::action G -->|Yes| I[Continue maintenance ESA]:::action H --> J[Monitor Hb, iron, BP]:::action ``` **High-Yield:** ESA (erythropoietin or darbepoetin alfa) is the first-line pharmacologic therapy for CKD anemia once iron stores are adequate. Do NOT measure serum EPO levels — they are elevated in CKD but remain insufficient to drive erythropoiesis. Clinical response (Hb rise) is the measure of ESA efficacy. ## Why NOT Measure EPO Level | Test | CKD Anemia | Rationale | | --- | --- | --- | | Serum EPO | Elevated (100–500 mIU/mL) | Kidneys cannot produce enough; absolute level is irrelevant | | Reticulocyte count | Low/inappropriately normal | Confirms hypoproliferative mechanism | | Iron studies | Normal (in this case) | ESA requires iron availability | | Bone marrow | Normal | Rules out other causes (aplasia, infiltration) | **Clinical Pearl:** Measuring serum EPO in CKD is a common misconception. EPO levels are already elevated in CKD; the problem is insufficient production relative to anemia severity. Starting ESA directly based on clinical criteria (Hb <10 g/dL in CKD) is the standard approach. **Tip:** Before starting ESA, ensure: 1. Iron stores adequate (ferritin >100 ng/mL, TSAT >20%) 2. No active infection or inflammation (CRP, WBC) 3. Reticulocyte count confirms hypoproliferation 4. Blood pressure controlled (ESA can raise BP) **Warning:** ESA target is Hb 10–12 g/dL in CKD; avoid Hb >13 g/dL due to increased thrombotic risk. Monitor for hypertension and thrombosis. [cite:Harrison 21e Ch 105; KDIGO 2021 Anemia in CKD] ![Anemias Overview diagram](https://mmcphlazjonnzmdysowq.supabase.co/storage/v1/object/public/blog-images/explanation/2613.webp)

Answer

A. Perform bone marrow biopsy to assess erythropoiesis

Answer

C. Measure serum erythropoietin (EPO) level

Answer

D. Start iron supplementation to optimize iron stores

A 52-year-old man with chronic kidney disease (eGFR 28 mL/min/1.73m²) presents with fatigue and dyspnea. His hemoglobin is 7.8 g/dL, MCV 82 fL, reticulocyte count 1.2% (normal 0.5–2.5%). Iron studies are normal. What is the most appropriate next step in management?

Explanation

Clinical Diagnosis

Management Algorithm for CKD Anemia

Why NOT Measure EPO Level

Practice similar questions

Join our NEET PG community

Test	CKD Anemia	Rationale
Serum EPO	Elevated (100–500 mIU/mL)	Kidneys cannot produce enough; absolute level is irrelevant
Reticulocyte count	Low/inappropriately normal	Confirms hypoproliferative mechanism
Iron studies	Normal (in this case)	ESA requires iron availability
Bone marrow	Normal	Rules out other causes (aplasia, infiltration)